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SRC is a non-receptor tyrosine kinase with key roles in breast cancer development and progression. 
Despite this, SRC tyrosine kinase inhibitors have so far failed to live up to their promise in clinical 
trials, with poor overall response rates. We aimed to identify possible synergistic gene-drug 
interactions to discover new rational combination therapies for SRC inhibitors. An unbiased genome-
wide CRISPR-Cas9 knockout screen in a model of triple-negative breast cancer revealed that loss of 
Integrin-linked kinase (ILK) and its binding partners α-Parvin and PINCH-1 sensitizes cells to 
bosutinib, a clinically approved SRC/ABL kinase inhibitor. Sensitivity to bosutinib did not correlate 
with ABL dependency; instead, bosutinib likely induces these effects by acting as a SRC tyrosine 
kinase inhibitor. Furthermore, in vitro and in vivo models showed that loss of ILK enhanced 
sensitivity to eCF506, a novel and highly selective inhibitor of SRC with a unique mode of action. 
Whole-genome RNA sequencing following bosutinib treatment in ILK knockout cells identified 
broad changes in the expression of genes regulating cell adhesion and cell-extracellular matrix. 
Increased sensitivity to SRC inhibition in ILK knockout cells was associated with defective 
adhesion, resulting in reduced cell number as well as increased G1 arrest and apoptosis. These 
findings support the potential of ILK loss as an exploitable therapeutic vulnerability in breast cancer, 
enhancing the effectiveness of clinical SRC inhibitors. 
Statement of Significance 
A CRISPR-Cas9 screen reveals that loss of integrin-linked kinase synergizes with SRC inhibition, 
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SRC family kinases are group of nine non-receptor tyrosine kinases of which SRC is the prototype. 
SRC is a key regulator of cell-matrix and cell-cell adhesions and is known to play important roles in 
a number of cancer-associated phenotypes including proliferation, migration and invasion. Disease-
associated upregulation of SRC kinase activity has been demonstrated in many malignancies, 
including breast, colon and gastric cancer. In breast cancer, elevated SRC expression is associated 
with poor prognosis (1). Despite the validated aetiological role of this target and several commercial 
drug discovery programs, there has been limited evidence of clinical efficacy in solid tumours, and 
no progress in understanding the molecular signatures that predict sensitivity to available inhibitors 
(2,3). Bosutinib (SKI-606) is a multi-kinase inhibitor and has activity against all nine SRC family 
members as well as ABL (4). Bosutinib is currently used as a second-line treatment for patients with 
chronic myeloid leukaemia that carry the BCR-ABL oncogene (5), and has shown activity in 
preclinical models of breast cancer (6,7). In a phase II clinical trial of bosutinib monotherapy in 
heavily pre-treated, advanced breast cancer patients, bosutinib presented poor overall response rates 
of 5.5% (8). However, there was evidence of disease stabilisation (37%), and together with the 
reported disease control rates following treatment with dasatinib, a multi-kinase inhibitor with 
activity against SRC family members (9), this suggests there is a subset of breast cancer patients that 
are responsive to dual SRC/ABL inhibition.  
One of the reasons that SRC/ABL tyrosine kinase inhibitors (TKIs) such as bosutinib have so far 
failed to live up to their promise in clinical trials is due to limited information on the molecular 
determinants of SRC inhibitor sensitivity. To address this, we undertook an unbiased genome-wide 
CRISPR-Cas9 screen in a model of triple-negative breast cancer (TNBC) to identify genes whose 
depletion alters the cellular sensitivity to bosutinib treatment. We show that loss of the cell-matrix 
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adhesion protein integrin-linked kinase (ILK) and its binding partners α-Parvin and PINCH-1 can 
potentiate the inhibitory effect of bosutinib.  
Materials and Methods  
Additional information on all Methods can be found in the Supplementary Information. 
Cell Culture 
All cell lines were grown in a humidified cell culture incubator at 37
o
C and 5% CO2. MDA-MB-231, 
MDA-MB-468, MDA-MB-157, MDA-MB-134-VI, SKBR3 and MCF-7 were maintained in DMEM 
+10% FBS. ZR-75-1 and T47D were maintained in RPMI-1640 +10% FBS. All cell lines were 
passaged for no more than 20 passages. Automated cell counts for passage calculations were 
obtained from the CellCountess II automated cell counter (Thermo Fisher Scientific). Cells were 
routinely tested for mycoplasma and were authenticated by STR profiling. 
2D cell viability assays 
Unless stated otherwise, cells were seeded at 1,000 cells/well into flat-bottom 96-well plates (Greiner 
655180). Edge wells were excluded and plates were left for 30 min RT before transferring to an 
incubator. Plates for real-time analysis were transferred to the IncuCyte FLR imaging system (Essen 
BioScience, USA) as previously described
(10)
. Unless stated otherwise, compounds were added (5 
μL/well) at two days post seeding, for five days. Compounds were reconstituted in dimethyl 
sulfoxide (DMSO). Plates were assayed for cell viability using the resazurin reduction assay and/or 
cell counts as described previously (10). The Spark 20M (TECAN) was used to quantify resazurin 
fluorescence following best practice procedures described previously (11). The ImageXpress system 
(Molecular Devices) was used to image Hoechst 33342 stained plates. CellProfiler 
(www.cellprofiler.org) was used to enumerate cell counts as previously described (12). Normalised 
cell viability was calculated as follows: sample / DMSO × 100. Relative half-inhibitory 
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concentrations (EC50) were calculated in Prism from the nonlinear regression algorithm of the 
normalised cell viability plotted against an 8-point compound dilution. 
3D spheroid cell viability assays 
Cells were seeded at 2,000 cells/well into round-bottom 96-well plates (Corning #7007). Once 
spheroids had formed over two to three days, plates were imaged at 4× magnification using the 
ImageXpress and subsequently compounds were added. On day seven post drugging, spheroids were 
stained with Calcein-AM (3.75 µM final) to give a ‘live cell’ readout, propidium iodide (1.0 µM 
final) or Draq7 (3.0 µM final) for a ‘dead cell’ readout and Hoechst 33342 (1.0 µM final) for a ‘total 
cells’ readout. The ImageXpress was used to create a single flattened maximum intensity projection 
from an eight-step Z stack with a 50 µM step size. A custom CellProfiler pipeline was used to 
quantify the spheroid area and intensity values for each spheroid. Data was normalised as follows: 
sample / DMSO × 100. 
Cell adhesion challenge 
Cells were seeded at 20,000 cells/well in serum-free media into 96-well plates (Greiner #655180). 
DMSO or bosutinib was added at the time of seeding. Plates were imaged every 10 min in the 
IncuCyte FLR for 2 h and then washed gently two times with 100 μL PBS taking care to not disrupt 
adhered cells. Plates were then returned to the IncuCyte for a final post-wash scan to determine the 
adhered cells. 
Western blotting 
Cell lysates were prepared in RIPA buffer (150 mM NaCl, 50 mM Tris pH 7.2, 0.1% SDS, 1.0% 
Triton X-100) with protease and phosphatase inhibitors (10 μg/mL aprotinin, 125 mmol/L 
phenylmethylsulfonyl fluoride, 100 μmol/L sodium orthovanadate, and 0.5 mmol/L sodium 
fluoride). For 3D spheroid protein extraction, spheroids were pooled and then solubilised in RIPA 
using sonication. Protein concentration was determined using the BCA protein assay kit. Whole-cell 
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lysates were fractionated by SDS-PAGE (20 µg per sample) and transferred onto nitrocellulose 
membranes. Primary antibodies used were: ABL (SCBT, #sc-23 and #sc-56887) and pY245 ABL 
(CST #2861); Arg (Ab134134); Cofillin (CST #5175); CrkL (CST #3182) and pY207 CrkL (CST 
#3181); FAK (CST #3285) and pY397 FAK (CST #3283); GAPDH (CST #5174); ILK (BD 
#611803 and Abcam #ab52480); mouse IgG1 (CST #5415); rabbit IgG (CST #2729); α-Parvin (CST 
#8190 and CST #4026); PINCH-1 (CST #11890); SRC (CST #2109) and pY416 SRC (CST #2101). 
Protein-antibody complexes were visualised by enhanced chemiluminescence detection (GE 
Healthcare) with horseradish peroxidase-conjugated secondary antibodies (CST #7076 and #7074) 
using the ChemiDoc XRS imaging system (Bio-Rad Laboratories). Experiments were repeated at 
least three times. Blots were cropped for clarity. The volume tool in Image Lab (v5.0) was used to 
quantify intensity. The same standard rectangle was used for each sample, as well as background 
correction for each lane.  
Genome-wide CRISPR-Cas9 dropout screen in MDA-MB-231 cells  
The CRSIPR screen was performed using the pooled lentiviral genome-wide CRISPR-SpCas9 
TKOv3 library targeting 18,053 protein-coding genes (4 gRNAs/gene), a gift from Jason Moffat 
(Addgene #90294), that was amplified and packaged into lentiviral particles (Vector Core, 
University of Michigan) as described (13). A total of 9 × 10
7
 MDA-MB-231 cells were transduced 
with the TKOv3 lentiviral library (71,090 gRNAs) at a low MOI (0.36) to ensure each cell receives 
only one sgRNA and to achieve >300-fold library coverage after selection. To select for 
transductants, 24 h after infection, cells were grown in the presence of 2.5 μg/mL puromycin for 48 
h, which was considered the initial time point (T0). Cells were then passaged every 3-4 days and 
library coverage of ≥300 cells per gRNA was maintained at every step. Seven days after puromycin 
selection (T7), two technical replicates containing 24 × 10
6
 cells were established for DMSO and 
bosutinib (provided by Pfizer), respectively. An EC20 concentration of bosutinib (0.9 μM) was added 
24 h post seeding for 3 days and cells were treated with bosutinib for five rounds or for ~12 
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population doubling times over 20 days. In order to capture the full representation of the screen, 25 × 
10
6
 cells were collected at each passage point for genomic DNA extraction using the QIAamp Blood 
Maxi Kit (#51192). The representation of genome-integrated gRNA sequences was determined using 
a two-step PCR in which the first step ‘PCR1’ amplifies the lentiviral sequence containing the 20 bp 
gRNA cassette from genomic DNA and the second step ‘PCR2’ attaches unique barcodes for sample 
deconvolution and Illumina TruSeq adapters (i5 and i7) for next-generation sequencing 
(Supplementary Figure 1, Supplementary Tables 1-3). The final pooled library was quantified with 
the Qubit 2.0 (Invitrogen) and Agilent 2100 Bioanalyser platforms. The diluted and denatured NGS 
library was sequenced on a NextSeq® 500/550 High Output Kit v2 (75 cycles) with a custom 'dark 
cycle recipe', for dual-index, single-read reads. Sequencing was performed by the Edinburgh 
Welcome Trust Clinical Research Facility. DrugZ (14) was used to calculate a gene-level normalised 
Z-score for determining significant differences between the DMSO and bosutinib samples at both 
T19 (three rounds of drugging) and T27 (five rounds of drugging). Gene copy number data was 
incorporated into the analysis as double-stranded DNA breaks from CRISPR-Cas9 can generate 
false-positive hits in genes with high copy numbers due to cutting-related genotoxicity (15). There 
was no correlation between gene copy number and gene-level normalised Z-score (Supplementary 
Table 4). Supplementary Dataset 1 contains the DrugZ results file. 
Interaction network analysis 
Composite functional association networks were constructed for putative enhancer and suppressor 
genes using GeneMANIA (version 3.5.2; human interactions: https://genemania.org/) in Cytoscape 
(version 3.8.0: https://cytoscape.org/). Network edges were weighted according to evidence of co-
functionality using GeneMANIA. Connected networks were clustered using the force-directed 
algorithm in the Prefuse toolkit (https://github.com/prefuse/Prefuse). 
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Patient survival analysis 
cBioPortal was used to download the METABRIC data (16) and the cancer genome atlas (TCGA-
PanCancer: http://cancergenome.nih.gov/) data. Data was analysed using the R packages survival 
(17), survival (18)
 
and their dependencies. In the METABRIC dataset, the TNBC subset was created 
from the clinical data for estrogen receptor alpha (ER), progesterone receptor (PR) and human 
epidermal growth factor receptor 2 (HER2). The TNBC subset had a 75% overlap with the PAM50-
basal METABRIC data. The TNBC subtype increased the total number of patients compared to the 
PAM50-basal subtype, thereby increasing the power of the statistical test for high vs low ILK. The 
optimal threshold for dichotomisation of the datasets into high and low ILK expression was identified 
using the survivALL R package and ‘plotALL’ function for multi-cut point analysis from the 
METABRIC dataset. The same dichotomisation threshold was then applied to the TCGA dataset in 
order to validate the cut point. 
CRISPR knockout of ILK and ABL1 in mammalian cells 
CRISPR-(e)SpCas9 target sites designed against ILK and ABL1 were created using the Broad 
Institute’s gRNA design tool (https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-
design), which uses the optimal gRNA and off-target design principles of Doench et al. (19). The 
gRNAs target exons 1 and 8 of ILK (deposited with Addgene plasmid #163320 and 163321), within 
the N-terminal ankyrin repeat domain-1 and the C-terminal protein kinase domain, respectively 
(Supplementary Table 5). For ABL1, the two designed gRNAs target exon 4 (Deposited with 
Addgene plasmid #163322 and 163323) within the protein kinase domain of both ABL1 isoforms 1a 
and 1b (Supplementary Table 6). The CRISPR plasmid constructs PX459v2 and eSpCas9(1.1) were 
purchased from Addgene (plasmid #62988 and #71814) and were deposited by Prof. Feng Zhang’s 
laboratory (20). The CRISPR-(e)Cas9 constructs were created as described by Ran et al. (21). 
Individual transfected cells (Nucleofector system (Lonza)) were selected for clonal expansion using 
puromycin selection (PX459v2) and flow cytometry. Monoclonal colonies were screened for loss of 
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the gene of interest using western blotting with the ILK monoclonal antibodies BD #611801 and 
Abcam #ab52480 or the ABL monoclonal antibodies 8E9 (sc-56887) and 24-11 (sc-23). The 
plasmids pDONR223-ABL1 (Plasmid #23939) and pLX301 (Plasmid #25895) were purchased from 
Addgene, and were deposited by William Hahn & David Root (22) and David Root (23), 
respectively. Using gateway cloning, pDONR223-ABL1 (containing the ABL1 isoform 1a (ABL1-
1A)) was cut and inserted into pLX301. 293T cells were used for viral packaging. 
Cell cycle analysis 
Cells were seeded in 6-well plates and drugged at either 48 h post seeding (48 h drug time-point) or 
72 h (24 h drug time-point). Cells were harvested using trypsin and fixed in cold 70% ethanol for 48 
h. Pellets were treated with RNAse H (NEB, #M0297L) and stained with 20 µg/ml propidium iodide. 
Cells were sorted on the BD LSRFortessa and analysed using BD FACSDiva software (v8.0.1). 
Apoptosis and cell death assay 
Cells were seeded in 6-well plates and drugged for 4 days. Medium was removed and spun down to 
include floating cells. Cells were then trypsinised and resuspended with 5% FBS in PBS. Cells were 
sorted on the BD LSRFortessa and analysed using BD FACSDiva software (v8.0.1). CellEvent 
Caspase 3/7 (apoptotic cells) and DAPI (dead cells) dyes were used. 
Breast cancer cell line datasets 
We generated a 16 BC cell line dataset for sensitivity to bosutinib using a PrestoBlue (Resazurin 
reduction) cell viability assay as described above (24). The cb5 cell line dataset is an integrated 
compendium of 5 Affymetrix datasets and was downloaded from Moleirinho et al. 2013 (25). 
Multiple cell line microarray datasets were combined for ILK expression levels in the 16 breast 
cancer cell lines. The Cancerxgene dataset was downloaded from: https://www.cancerrxgene.org/. 
The Cancerxgene dataset included 43 BC cell lines with data for bosutinib treatment. The Depmap 
interactive website is available at: https://depmap.org/portal/. The Depmap interactive portal of 20 
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BC cell lines used bosutinib cell viability data compared to ILK RNAseq expression levels and ILK 
relative protein expression. 
RNA sequencing 
Bosutinib EC20 (0.9 μM) or DMSO were added to cells at 24 h post seeding in 10 cm dishes. Three 
independent experimental replicates were performed. Total RNA was extracted at 72 h post drugging 
using RNAeasy Miniprep Kit (Qiagen) according to the manufacturer’s protocol. RNA quality and 
integrity were assessed on the Fragment Analyser Automated Capillary Electrophoresis System 
(Agilent Technologies). RNA yield and DNA contamination was quantified using the Qubit 2.0. 
Library preparation and sequencing was performed by the Edinburgh Welcome Trust Clinical 
Research Facility. The Lexogen QuantSeq 3’mRNA-Seq Library Prep Kit (FWD) for Illumina was 
used to generate libraries from 200 ng total RNA. Library quantity and quality were assessed using 
Qubit 2.0 and the Bioanalyser. Single-read sequencing was performed using the NextSeq 500/550 
High-Output v2.5 (75 cycles) Kit on the NextSeq 550 platform (Illumina). Demultiplexed FASTQ 
files with md5 checksums were imported into the Lexogen Bluebee platform and the Quantseq 2.3.6 
FWD pipeline was used. Trimming was performed using bbduk v35.92. STAR v2.5.2a (26) was used 
to align the read data to human genome build human GRCh38. The expected counts from HTSeq-
count v0.6.0 were imported into the statistical software package R (www.r-project.org). Differential 
expression analysis was undertaken with the EdgeR (v3.26.8) and Limma (v3.40.6) packages. 
Significantly differentially expressed genes were determined using the FDR (Benjamini & 
Hochberg) p-value adjustment <0.05 and a log2 fold change of ±1. Gene ontology (GO) functional 
enrichment analysis was carried out using ToppGene (https://toppgene.cchmc.org/). Read count and 
differential expression analysis data is available in Supplementary Datasets 2-5. 
Tumourigenicity assay 
Immunodeficient Rag2-Il2rg double knockout mice (R2G2) were obtained from Envigo, UK. Female 
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PX45v2 or ILK gRNA 2 cells (100 μL in PBS). Once tumours developed, mice were randomized 
(using the standard RAND function in Microsoft Excel) to daily oral gavage with either vehicle (50 
mM lactic acid with 0.1M NaOH, pH 6), eCF506 (40 mg/kg body weight, 0.1 mL/20 g) or bosutinib 
(75 mg/kg body weight, 0.1 mL/20 g). Statisticians were blinded to treatment group allocation. Mice 
were monitored twice weekly and culled if they became sickly or tumours had reached a maximum 
size of 15 mm. Tumours were collected at the end of the study. Formalin-fixed tissues were 
processed into paraffin wax blocks. Sections were cut, dewaxed and rehydrated before heat mediated 
antigen retrieval in sodium citrate buffer. After blocking, sections were incubated with Ki67 
antibody at 1:400 (Cell Signalling Technology #9027) followed by 3,3’-diaminobenzidine (DAB) 
Chromagen (Agilent #K3468) for visualisation. Sections were counterstained with hematoxylin and 
QuPath used to quantify Ki67 positive nuclei (https://qupath.github.io/). All animal studies and 
procedures were approved by the University of Edinburgh Ethical review committee (Application 
#116-WGH-20) and conducted in accordance with United Kingdom Home Office regulations. 
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Bosutinib demonstrates antiproliferative activity in several breast cancer cell lines 
Due to limited published data on sensitivity to bosutinib in breast cancer cell lines (6), we tested a 
panel of eight cell lines in both 2D and 3D viability assays. Bosutinib sensitivity did not correlate 
with breast cancer subtype in our cell line panel (Figure 1A and Supplementary Table 7), however 
the triple-negative MDA-MB-231 and the luminal A MCF-7 cell lines were the most sensitive to 
bosutinib.  
Both cell lines were more sensitive to bosutinib in a 3D spheroid growth assay (Figure 1A). 
However, although the half maximal effective concentration (EC50) values for bosutinib were in the 
sub-micromolar range for both MDA-MB-231 and MCF-7 cells, no significant cell death was seen at 
these concentrations using a 3D spheroid live/dead assay (Figure 1B and Supplementary Figure 2A). 
In both cell lines, bosutinib treatment caused a dose-dependent decrease in spheroid area 
(EC50=0.151 µM and 0.194 μM, respectively), but no corresponding decrease in Calcein-AM (viable 
cells) or increase in propidium iodide intensity (dead cells) until concentrations greater than 3 µM.  
We confirmed that bosutinib was inhibiting its designed targets SRC and ABL in the spheroid assay 
by western blot, where bosutinib treatment resulted in a dose-dependent reduction in pY419-SRC, 
with almost complete inhibition (~90% reduction) at 0.1 µM (Figure 1C, and Supplementary Figure 
2B). Total SRC was increased, as has been reported following treatment with SRC inhibitors (27). 
There was a marked reduction in ABL phosphorylation at Y245, a site required for its kinase 
activity, following treatment with bosutinib at 30 and 100 nM for the MDA-MB-231 and MCF-7 
cells, respectively. This correlated with a 90% and 70% reduction in pY207-CRKL at 30 nM in the 
MDA-MB-231 and MCF-7 cell lines, respectively (Figure 1C and Supplementary Figure 2C). 
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To provide mechanistic insight into the molecular pathways underlying bosutinib sensitivity, we 
performed a reverse-phase protein array (RPPA) analysis using 125 antibodies covering a panel of 
signalling proteins and phosphoproteins in MDA-MB-231 and MCF-7 cells following treatment with 
bosutinib (Supplementary Figure 3). This identified 17 and 7 significantly differentially regulated 
proteins and phosphoproteins in MDA-MB-231 and MCF-7 cells, respectively (p-value <0.05, log2 
fold change ±0.75). As expected, bosutinib treatment inhibited its designed targets SRC and ABL, 
with a significantly decreased signal intensity in SRC autophosphorylation at tyrosine (pY)419 (70% 
reduction at 1.25 µM), as well as an 80% and 70% reduction in pY207-CRKL, a key substrate of 
ABL, at 1.25 µM for the MDA-MB-231 and MCF-7 cells, respectively (Supplementary Figure 3). 
Other consistent changes that were seen between the cell lines included a decrease in pY15 CDK1 
and total CDK1, and a decrease in phosphorylation of phospho-threonine (pThr)183-JNK 
(Supplementary Figure 3A). 
Loss of ABL does not alter bosutinib effects in MDA-MB-231 and MCF-7 cells 
As bosutinib is a dual SRC/ABL inhibitor, which effectively inhibited ABL activity in both the 
MDA-MB-231 and MCF-7 cell lines, we asked whether the antiproliferative activity of bosutinib 
was due to ABL inhibition. We created ABL1 knockout isogenic cell lines using CRISPR-eCas9 
(Supplementary Figure 4A). Using 2D cell viability assays there were no differences between 
bosutinib EC50 values for the ABL1 knockout MCF-7 or MDA-MB-231 cell lines compared to the 
parental cells or ABL1 knockout cell lines in which ABL1 was re-expressed (Figure 1D). Similar 
results were observed with three other MDA-MB-231 ABL1 gRNA cell lines (Supplementary Figure 
4B). Loss of ABL1 also did not alter the sensitivity to bosutinib in the 3D spheroid assay 
(Supplementary Figure 4C). Thus, loss of ABL1 does not alter bosutinib activity in MDA-MB-231 
and MCF-7 cells in both 2D and 3D assays, indicating that bosutinib is unlikely to act via ABL1 
inhibition. 
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A genome-wide CRISPR-Cas9 knockout screen identifies the ILK-Parvin-PINCH complex as a 
key determinant of bosutinib sensitivity 
To identify genes that can alter bosutinib sensitivity we performed an unbiased genome-wide 
CRISPR-Cas9 negative selection screen in the MDA-MB-231 cell line (Figure 2A). We chose the 
Toronto knockout version 3 (TKOv3) library (13) that contains sequence-optimised guide RNA 
(gRNA) following empirically determined on- and off-target prediction enabling increased accuracy 
and scalability of the CRISPR screen. Cells were transduced with the lentiviral TKOv3 library at a 
low multiplicity of infection (MOI=0.36) and selected with puromycin. Since almost complete 
modification of genomic loci occurs after seven days of CRISPR treatment (28), cells were passaged 
for seven days after puromycin selection (T7), after which either an EC20 concentration of bosutinib 
(0.9 μM) or DMSO as a control were added 24 h post seeding for 3 days. A 24 h time point for 
bosutinib addition was chosen in order for cell attachment to occur, but before log-phase growth 
began. Cells were treated in this way for around 12 population doubling times (PDs) over 20 days. 
The screen was performed in technical duplicates and genomic DNA was extracted and genome-
integrated gRNA sequences were amplified and labelled with barcodes via a 2-step polymerase chain 
reaction (PCR). Next-generation sequencing was used to quantify the library representation of the 
gRNA sequences and DrugZ (14) was used to calculate gene-level normalised Z-scores for 
determining differences between the DMSO and bosutinib samples at the T19 (~7 PDs) and T27 
(~12 PDs) time points (Figure 2A). This allowed the identification of enhancer genes whose loss of 
function enhance sensitivity to bosutinib and suppressor gene interactions whose loss of function 
reduce bosutinib efficacy.  
Hierarchical cluster analysis of the individual gRNAs from the top enhancer and suppressor genes 
revealed groupings of replicates and treatments across time points, emphasising consistency in the 
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results between the T19 and T27 time points at the gRNA level (Supplementary Figure 5A). DrugZ 
analysis of the T27 time point identified 19 enhancer genes and 23 suppressor genes with a 
significant gene-level normalised Z-score (FDR<0.05) with 12 enhancer genes and 15 suppressor 
genes also identified at the T19 time point (Figure 2B and Supplementary Figure 5B). Integrin-linked 
kinase (ILK) and α-Parvin (PARVA) were the highest ranked enhancer genes at both the T27 and T19 
time points. PINCH-1 (LIMS1) also had a significantly decreased gene-level normalised Z-score 
upon bosutinib treatment at both time points (Supplementary Table 4). These three proteins form the 
ILK-Parvin-PINCH (IPP) complex. The IPP complex tethers cells to their surrounding environment 
via integrins and is involved in cytoskeleton remodelling, angiogenesis, proliferation, survival and 
differentiation (29). Hence, within the pool of CRISPR knockout cells, those cells with loss of ILK 
or its binding partners α-Parvin and PINCH-1 significantly enhanced the inhibitory effect of 
bosutinib on MDA-MB-231 cell growth.  
Functional network analysis revealed connectivity between many of the top enhancer genes (Figure 
2C and Supplementary Figure 6A). Interestingly, both the expected targets of bosutinib, SRC and 
ABL, and many of the enhancer genes, such as those involved in the IPP complex, AMBRA1, EED 
and TYMS, converge on the focal adhesion kinase (FAK) network (Supplementary Figure 6B) and 
are linked to cytoskeletal organisation. Consistent with this, gene ontology (GO) analysis of the top 
enhancer genes centred around the interactions of the IPP complex. The key enriched molecular 
pathways were adherens junctions, cell-extracellular matrix (ECM) interactions, focal adhesions and 
the regulation of cytoskeletal remodelling and cell spreading (Figure 2D). There were also a number 
of interesting suppressor genes such as CBFB, RUNX1, EP300 and AHR, but no GO terms were 
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Loss of the ILK-Parvin-PINCH complex enhances sensitivity to bosutinib 
We focused on ILK as the top ranked enhancer gene for validation studies. Analysis of the 
METABRIC and TCGA-PanCancer breast cancer datasets showed that high ILK expression was 
significantly associated with poor breast cancer-specific survival for the TNBC and basal subtypes 
(Kaplan Meier log-rank test, p<0.05), but not for the remaining breast cancer patients (Figure 2E-F 
and Supplementary Figure 7), suggesting a functional role for ILK in these subtypes. To validate that 
loss of ILK, α-Parvin or PINCH-1 can potentiate the inhibitory effect of bosutinib, we generated 
clonal ILK knockout cell lines. We created MDA-MB-231 ILK knockout cell lines using two gRNAs 
targeting ILK and a transiently expressed CRISPR-Cas9 system (PX459v2) to generate single-cell-
derived cell lines lacking ILK. We generated three cell lines for ILK gRNA 1 and three for ILK 
gRNA 2 (Supplementary Figure 8A). The IPP complex members are interdependent for their protein 
stability (30). Accordingly, our western blot analysis showed that ILK knockout in MDA-MB-231 
cells resulted in the downregulation of PINCH-1 and α-Parvin in addition to loss of ILK (Figure 3A 
and Supplementary Figure 8A). Therefore, we did not endeavour to create PINCH-1 or α-Parvin 
CRISPR knockouts in addition to the ILK knockout cell lines. 
We next assessed the impact of bosutinib treatment on cell viability in cells with or without ILK. 
Loss of ILK resulted in a ~4-fold decrease (p-value <0.0001) in the EC50 of bosutinib compared to 
the empty-gRNA CRISPR control (PX459v2) (Figure 3B). ILK loss alone did not impact the growth 
rate of the cells, as assessed by the change in cell confluence over time (Figure 3C). At the EC20 
concentration of 0.9 μM, bosutinib significantly decreased the real-time growth of all MDA-MB-231 
ILK knockout cell lines compared to the PX459v2 control (Figure 3C and Supplementary Figure 
8B). This resulted in a ~3-fold change decrease in cell confluence between cells with ILK loss and 
the PX459v2 control at the end of the assay (Figure 3D). Bosutinib treatment also resulted in a 
significant decrease in cell number in all six MDA-MB-231 ILK knockout cell lines compared to the 
PX459v2 control (Figure 3E, Supplementary Figure 8C). A similar enhancement of bosutinib 
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activity was seen in the T47D breast cancer cell line following knockdown of ILK (Supplementary 
Figure 8D, E). Cell cycle analysis revealed no changes in cell cycle distribution upon ILK loss or 
bosutinib treatment (EC20, 0.9 μM). However, there was an increased G1 phase arrest (p-value 
<0.05) when ILK knockout cells were treated with bosutinib (Supplementary Figure 8F). Notably, 
there was also a 4-fold increase (p-value <0.0001) in the percent of apoptotic cells when ILK 
knockout cells were treated with bosutinib compared to PX459v2 control cells (Figure 3F). Taken 
together, these data confirm that loss of ILK in MDA-MB-231 cells enhances sensitivity to bosutinib 
through an enhanced G1 arrest and increased apoptosis. 
SRC but not ABL is responsible for the increased activity of bosutinib in combination with 
ILK loss 
The other designed target of bosutinib is SRC. However, as there are nine SRC family members it is 
difficult to create suitable knockouts. In this respect, the SRC-specific inhibitor eCF506 is an 
effective tool compound as it inhibits all nine SRC family members and has been shown to have a 
1,000-fold selectivity for SRC over ABL and potent growth inhibitory effects in both MDA-MB-231 
and MCF-7 cell lines (24,27), supporting the importance of SRC activity in driving their 
proliferation. 2D cell viability assays confirmed that there were no differences between eCF506 EC50 
values for the ABL1 knockout MDA-MB-231 cell lines compared to the parental cells 
(Supplementary Figure 9A). However, in the ILK knockout cells there was a ~4-fold decrease (p-
value <0.0001) in the EC50 for eCF506 compared to the PX459v2 CRISPR control cells (Figure 4A). 
Similar to bosutinib, analysis of apoptotic cells revealed a 6-fold increase (p-value <0.0001) in 
Caspase 3/7 positive cells upon eCF506 inhibition (40 nM; EC20) in ILK depleted cells compared to 
the PX459v2 control cells (Figure 4B). In addition, cell cycle analysis showed a small but consistent 
increase in the G1 peak for eCF506 in ILK depleted cells (Supplementary Figure 8F). Treatment of 
the MDA-MB-231 ILK knockout isogenic cell lines with the ABL allosteric inhibitor GNF-2 (31) did 
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not change cell viabilities (Supplementary Figure 9B). As expected, addition of eCF506 to the 
PX459v2 MDA-MB-231 cells resulted in a significant reduction in cell growth as measured in real-
time in the IncuCyte and end-point cell counts (Figure 4C). Similar to bosutinib treatment, the 
combined effect of ILK loss and eCF506 treatment (60 nM; EC30) resulted in a further significant 
decrease in cell growth as well as cell counts compared to the PX459v2 control (Figure 4D-E). Thus, 
loss of ILK in the MDA-MB-231 cell lines enhanced the effects of SRC inhibition in the absence of 
ABL inhibition. These findings taken together confirm that SRC inhibition is required for the 
decreased viability in cells with ILK loss following treatment with bosutinib or eCF506. 
Low ILK expression moderately correlates with sensitivity to bosutinib 
To establish whether ILK expression was associated with bosutinib sensitivity in a larger panel of 
breast cancer cell lines, Pearson’s rank correlation coefficients were used as a measure of the 
strength of association between sensitivity to bosutinib and ILK mRNA expression levels in three 
different cell line datasets, two publicly available and one in-house (Supplementary Table 9, 
Supplementary Figure 10). We generated a dataset from 16 breast cancer cell lines using EC50 cell 
viability measurements to determine sensitivity to bosutinib (24). For ILK mRNA expression, we 
used an integrated compendium of 5 Affymetrix cell line datasets (cb5) (25). Decreased ILK 
expression correlated with a lower bosutinib EC50, although with only a moderate effect size 
(Pearson’s: r(61) = 0.358, p = 0.004). The publicly available Cancerxgene dataset allowed us to 
include 43 breast cancer cell lines with data for bosutinib treatment queried against the cb5 dataset. 
This also resulted in a weak but positively correlated relationship (Pearson’s: r(119) = 0.283, p = 
0.002). Similar correlations were seen between bosutinib sensitivity and LIMS1 and PARVA in these 
two datasets (Supplementary Table 9). Additionally, we utilised the Depmap
 
interactive portal of 20 
breast cancer cell lines with bosutinib cell viability data compared to ILK RNAseq and protein 
expression levels. Although this dataset had a positive correlation for both RNAseq and protein 
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expression it was not significant (Pearson’s: r(18) = 0.395, p = 0.085 and r(18) = 0.299, p = 0.199, 
respectively), while the correlation with LIMS1 and PARVA was significant (Supplementary Table 
9). The small number of cell lines in these datasets which have low ILK expression limits the 
predictivity of these analyses, but taken together suggest that ILK gene expression or protein alone is 
not sufficient to predict sensitivity to bosutinib.  
In order to look at gene expression of ILK in human breast tumours, we utilised an integrated 
compendium of 17 Affymetrix datasets (cb17) representing 2,996 breast cancers (25). This dataset 
has detection calls calculated from perfect and mis-matched probes, which effectively indicate 
whether genes are detectably ‘present’ or ‘absent’ in each sample. The basal subtype had 
significantly lower ILK expression (Tukey one-way ANOVA, p<0.001) compared to all other 
subtypes (Supplementary Figure 11A). Interestingly, ILK was significantly called ‘absent’ in 15% of 
basal breast tumours (Chi-square test, p<0.001) compared to around 6% for other subtypes 
(Supplementary Figure 11B, C). Although METABRIC and TCGA-PanCancer samples do not have 
‘absent’ or ‘present’ detection calls, ILK expression was significantly lower in the basal subtype 
(Tukey HSD, p< 0.05) compared to all other subtypes except HER2 (Supplementary Figure 11D). A 
similar pattern was seen for PARVA but not LIMS1, other components of the IPP complex. 
Interestingly, in the same datasets SRC was higher in the basal subtype (Supplementary Figure 11D). 
It remains to be established whether there is a small subset of patients that would benefit from 
bosutinib treatment due to the absence of ILK, and the sensitisation of the luminal A T47D cell line 
to SRC inhibitor treatment following loss of ILK, indicates that this will not be subtype specific.  
ILK loss in combination with bosutinib regulates extracellular matrix and adhesion protein 
transcripts 
We undertook an unbiased genome-wide RNA sequencing approach to understand and exploit the 
mechanism(s) at the transciptional level that enabled ILK loss to potentiate SRC inhibition in our 
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TNBC model. Principal component analysis identified good clustering of similar samples and 
separation between different groups. Hierarchical clustering of log2 counts per million for the 500 
most variable genes across all 12 samples also correctly clustered samples (Supplementary Figure 
12A). The largest variation (dimension 1) was seen between the presence or absence of ILK which 
resulted in 444 DEGs (Figure 5A, B). This identified genes associated with the ECM, actin 
cytoskeleton, membrane structures, integrin and growth factor binding (Supplementary Figure 12B) 
consistent with ILKs known role in cell-matrix adhesions. For the MDA-MB-231 PX459v2 CRISPR 
control, bosutinib treatment resulted in 392 DEGs (DEGs; log2 fold change ±1 and p-value < 0.05) 
(Figure 5B). Importantly, there were 504 DEGs unique to the combination of ILK loss and bosutinib 
addition (Figure 5B). To determine the magnitude of change in the 504 uniquely DEGs we compared 
the normalised read counts for bosutinib treatment with or without ILK. This resulted in 134 genes 
with significant (log2 fold change ±1 and p-value <0.05) changes upon bosutinib addition and ILK 
loss (Figure 5C). These 134 DEGs are shown across all samples, confirming that the changes are 
unique to bosutinib treatment of ILK knockout cells (Figure 5D). These uniquely DEGs were 
involved in ECM and cell adhesion processes as shown using ToppGene (Figure 5E). Network 
analysis of the 134 unique DEGs revealed a number of interactions with the most prominent being a 
collagen-integrin network of associated genes (Figure 5F), but also adhesion complex associated, and 
ECM-related gene expression interactions (Supplementary Figure 12C). Clearly, cell adhesion and 
cell-ECM interactions were the core effected processes in the context of ILK knockout-mediated 
bosutinib sensitivity, suggesting they may be responsible for the increased sensitivity to bosutinib 
observed in the ILK depleted cells. 
ILK knockout in combination with bosutinib causes cell adhesion defects 
The IPP complex members and SRC are involved in regulating cell matrix adhesion. Taken together 
with the RNAseq data, this suggested that defective adhesion may be involved in the increased 
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sensitivity to bosutinib eCF506 treatment in ILK knockout cells. To characterise the adhesive defects 
in the ILK knockout cells, we first analysed their focal adhesions by carrying out 
immunofluorescence using a number of antibodies against adhesion proteins (Supplementary Figure 
13A, B). Using paxillin as a marker of focal adhesions, we showed that adhesion length was 
significantly reduced in the ILK knockout cells. Furthermore, the distribution of adhesions, was also 
altered: ILK knockout cells lacked fibrillar adhesions located towards the centre of a cell. These 
fibrillar adhesions are distinguished from focal adhesions by their low or absent phosphotyrosine 
content as was also seen in the ILK knockout cells. Fibrillar adhesions evolve from mature focal 
adhesions indicating that the ILK knockout cells have a defect in focal adhesion maturation.  This has 
been described previously in ILK knockout fibroblasts (30). Integrin clustering in focal adhesions 
results in the activation of FAK at the tyrosine (Y)397 autophosphorylation site. Consistent with 
decreased integrin activation, ILK loss decreased pY397-FAK by 2.4-fold (p-value= 0.047; Figure 
6A; quantification Supplementary Figure 13C). We then measured cell-substrate adhesion following 
an adhesion ‘challenge’ with a gentle PBS wash. In the ILK knockout cells, there was a complete 
loss of adherent cells following the adhesion challenge (Figure 6B; data for additional ILK gRNA 
lines shown in Supplementary Figure 13D). Interestingly, bosutinib, but not eCF506, caused an 
increase in cell adhesion after the adhesion challenge in the control cells, but both drugs were not 
able to rescue the adhesion defect in the ILK knockout cells (Figure 6B and Supplementary 13D). It 
is not clear why bosutinib increases adhesion in the control cells as the reduction in adhesion 
observed with eCF506 is more consistent with the well documented role of SRC family kinases in 
cell-matrix adhesion (32). eCF506 reduced pY397-FAK levels in both control and ILK knockout 
cells. This can be attributed to the ability of eCF506 to bind SRC in an inactive conformation leading 
to destabilisation of the FAK-SRC complex and a loss of FAK phosphorylation. In contrast, 
bosutinib binds SRC in an active conformation, thus stabilising FAK-SRC binding and Y397-FAK 
phosphorylation (24). The loss of ILK did not alter the ability of SRC and FAK to form a complex, 
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although the levels of pY397-FAK complexed with SRC was reduced reflecting the reduced 
phosphorylation of FAK on Y397 in the ILK knockout cells (Supplementary Figure 13E).  
To address whether inhibition of FAK, could also synergise with ILK loss, ILK knockout cells were 
treated with the FAK inhibitor PND-1186. There was no difference in EC50 values for PND-1186 
between the PX459v2 and ILK knockout cells, although pY397-FAK was effectively inhibited in 
both (Figure 6C and Supplementary Figure 14A). pY419-SRC was unaltered following PND-1186 
treatment (Supplementary Figure 14A, B). Previous studies have shown that inhibition of FAK is not 
sufficient to reduce phosphorylation of SRC and its substrates in integrin adhesion complexes 
suggesting that either the residual FAK activity is sufficient to maintain SRC-dependent 
phosphorylation events, or that SRC is activated in a FAK-independent manner (33). To determine 
whether downstream signalling pathways were differentially regulated following FAK and SRC 
inhibitor treatment in the ILK knockout cells, a RPPA was carried out. This identified 24 and 10 
uniquely differentially regulated proteins and phosphoproteins following bosutinib and PND-1186 
respectively (p-value <0.05, log2 fold change), while 13 were common to both drugs 
(Supplementary Figure 14C). Taken together these data suggest that although SRC and FAK have 
overlapping functions the reduction in Y397-FAK phosphorylation following FAK inhibitor 
treatment is not sufficient to prevent downstream SRC signalling and/or that they have independent 
signalling roles.  
Initial microscopy observations showed that bosutinib treatment (EC20; 0.9 μM) led to a rapid 
“rounding up” of MDA-MB-231 ILK
 
knockout cells within one hour of addition (Supplementary 
Figure 15A, B). We investigated this change by quantifying the number of total and ‘rounded cells’ 
following bosutinib treatment using the IncuCyte S3 (Figure 6D). Within the first hour of bosutinib 
addition, there was an increase in the number of rounded cells (cells with an area <600 μm
2
 and 
eccentricity <0.65): in the ILK knockout cells there was a 2.6-fold increase in rounded cells (p-value 
<0.0001) following bosutinib treatment compared to the ILK gRNA 2 DMSO-treated cells (Figure 
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6D). This cell rounding was accompanied by an immediate decrease in total cell number in the 
MDA-MB-231 ILK knockout cells, but not PX459v2 cells (Figure 6E), and a 3.0-fold reduction (p-
value <0.0001) in cell number after 72 h in the ILK knockout cells as well as a 1.3-fold reduction (p-
value =0.045) in the PX459v2 cells. Tracking of apoptotic cells using a fluorescent reporter of 
caspase 3/7 activity showed that apoptotic cell numbers correlated with the rounded phenotype 
(Supplementary Figure 15C, D). Taken together with the increased apoptosis observed by FACS in 
the ILK knockout cells following treatment with bosutinib over 4 days (Figure 3F), this indicates that 
the cell rounding and loss of adhesion contributes to the cell death and decreased cell numbers 
observed. Thus, the increased sensitivity to bosutinib following ILK loss can be attributed to reduced 
adhesiveness when SRC inhibition is combined with ILK loss. Interestingly, siRNA targeting of ILK 
in MDA-MB-231 cells did not result in enhanced sensitivity to bosutinib or eCF506 despite reducing 
ILK by 90% (Supplementary Figure 16), suggesting that complete loss of ILK is required to disrupt 
adhesion complexes in the MDA-MB-231 cells. In support of this, quantification of focal adhesions 
in the siRNA ILK treated cells showed that there was no difference in focal adhesions in contrast to 
the disruption of adhesions seen in the sgRNA ILK knockout cells (Supplementary Figure 13B).  
ILK loss enhances SRC inhibition in vivo 
Finally, we characterised the effect of combined SRC inhibition and ILK loss on tumour growth in 
vivo. Immunodeficient R2G2 mice were subcutaneously injected with MDA-MB-231 cells with or 
without ILK, and once tumours had established, were treated with either bosutinib or eCF506 at 
doses previously shown to inhibit SRC activity in tumours (24)(Figure 7A). The rapid growth of the 
control tumours resulted in all animals being sacrificed by day 24 of treatment which was extended 
to day 28 in the bosutinib treated animals. In contrast eCF506 reduced the growth of the control 
tumours and all animals were sacrificed at day 35 at the end of the experiment. There was a delay in 
tumour growth in the ILK gRNA tumours, but once established the tumours also grew rapidly and 
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animals were sacrificed after 35 days of treatment. Treatment with eCF506 completely blocked the 
growth of the ILK gRNA tumours (Figure 7A) and analysis of the final tumours showed a significant 
reduction in tumour volumes (Figure 7B). Western blot analysis confirmed effective inhibition of 
SRC in tumours from both the bosutinib and eCF506 treated animals (Figure 7C, D). Ki67 positivity 
in the tumours was analysed as a measure of proliferation and showed that there was no difference in 
the proliferation of the ILK deficient tumours compared to the controls at the end point of the study 
when the tumours were collected (Figure 7E). Taken together with the lack of effect of ILK loss on 
proliferation in 2D (Figure 3C), this indicates that ILK is not required for the intrinsic proliferative 
capacity of the cells. Bosutinib treatment prevented the rapid growth of the ILK gRNA tumours at 
the later time points, however final tumour volumes and Ki67 positivity were not significantly 
different between the ILK gRNA vehicle and bosutinib treated animals (Figure 7). In contrast 
treatment with eCF506 completely blocked the growth of the ILK knockout tumours. The difference 
in activity of bosutinib and eCF506 is not fully understood but may reflect the reported ability of 
eCF506 to inhibit SRC in an inactive conformation leading to disruption of protein-protein 
interactions in addition to inhibition of SRC kinase activity (24), as pY418 SRC was reduced in both 
bosutinib and eCF506 treated tumours (Figure 7C, D). 
Discussion 
SRC/ABL TKIs such as bosutinib and dasatinib have been investigated for treating breast cancer for 
some time (6,8,9,34,35). Yet so far these drugs have had limited clinical efficacy in solid tumours, 
despite attempts to validate potential gene-signatures of sensitivity (36,37). We aimed to identify 
possible synergistic gene-drug interactions in an attempt to understand the molecular determinants of 
bosutinib sensitivity and discover new rational combination therapies for SRC inhibitors. Using an 
unbiased genome-wide CRISPR-Cas9 knockout screen, we identified loss of the ILK-Parvin-PINCH 
complex as the key enhancer of SRC inhibition in in vitro and in vivo breast cancer models. ILK 
serves as a key scaffold protein in cell–matrix interactions and focal adhesions, tethering cells to 
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their surrounding environment and interacting with multiple signaling pathways through interactions 
with its binding partners Parvin and PINCH (29). Furthermore, Horton and co-workers identified a 
consensus integrin adhesome comprising 60 proteins representing the core cell adhesion machinery 
which is centred around four functionally interconnected axes, with the ILK-PINCH-PARVIN 
complex segregating into one of these (38). SRC is also a key regulator of integrin adhesions and 
ILK is known to interact with the SH3 domain of SRC demonstrating interconnected signalling 
pathways (39). However, they also have distinct biological activities and our data support a model in 
which targeting either SRC or ILK alone is not sufficient to inhibit proliferation and induce 
apoptosis, but that taking out both of these integrin complex components has a synergistic effect. The 
RNASeq analysis identified a number of integrins and ECM proteins to be significantly differentially 
expressed in the ILK knockout cells, with further changes in adhesion related genes seen following 
treatment with bosutinib. This supports defective adhesion signalling as being the critical pathway 
involved in the enhanced sensitivity to bosutinib. Interestingly there was no synergism between loss 
of ILK and treatment with the FAK inhibitor PND-1186 suggesting that the decreased activity of 
FAK in the ILK knockout cells is already sufficient to disrupt adhesion signalling and prime 
sensitivity to SRC inhibition. Previous studies have shown that SRC and FAK inhibitors can reduce 
the phosphorylation of different proteins within integrin adhesion complexes, and that FAK 
inhibition is not sufficient to reduce phosphorylation of SRC substrates (33). Taken together with our 
data, this suggests that although SRC and FAK have overlapping functions, the reduction in pY397-
FAK following FAK inhibitor treatment is not sufficient to prevent downstream SRC signalling 
and/or that they have independent signalling roles. Indeed, analysis of signalling pathways that were 
altered following treatment with either bosutinib or PND-1186 revealed a number of differences in 
the ILK knockout cells. A greater understanding of the interplay between ILK, SRC and other 
adhesion signalling pathways in tumours will be required to fully exploit this vulnerability. 
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Upregulation of ILK is frequently observed in cancer tissues such as breast, colorectal and prostate 
(40). In addition, in prostate cancer, ILK expression is a promising prognostic marker and is 
correlated with tumour grade, progression and 5-year survival (41). In breast cancer there is limited 
data, but one study has reported that ILK overexpression is associated with poor overall survival 
using immunohistochemistry methods (42), and that mRNA levels are higher in tumour compared to 
adjacent non-cancerous tissues. We utilised the two largest publicly available breast cancer gene 
expression datasets (METABRIC and TCGA) to show that high ILK expression is associated with 
poor outcomes for the TNBC and basal subtypes. This is consistent with a number of in vitro and in 
vivo studies that have reported ILK-dependent effects on breast cancer proliferation, migration, 
invasion and tumour growth and initiation (43). Whether there is a subtype specific role for ILK in 
breast cancer remains to be established.  
The potential of ILK as an anticancer target has been recognised for a number of years, with a 
number of putative inhibitors showing significant suppressive effect on cancer development and 
progression and hence a potential to target ILK for cancer treatment (40). However, although it was 
originally thought that ILK exerts its oncogenic effects via its kinase domain, mammalian ILK lacks 
kinase activity (44,45) and thus off-target effects are anticipated for small molecules designed to 
target ILK kinase activity (e.g. Cpd 22 (46), QLT0267 (47) and QLT0254 (48)). These putative 'ILK 
inhibitors' in our hands and others (49) do not act via ILK kinase inhibition and do not mimic ILK 
knockdown (49). Notably, a recent study in a model of chronic myeloid leukemia has found QLT-
0267 synergises with dasatinib treatment (50); however, they did not demonstrate that it was working 
via inhibition of ILK kinase activity, and further investigation into the potential mechanism is 
required. There is therefore a need to create new bona fide ILK inhibitors that could be used in 
combination with SRC kinase inhibitors such as bosutinib and eCF506. One possibility is the 
development of drugs that can disrupt the IPP complex, which has shown some promise (51). This 
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work provides the first step towards new rational drug combinations of ILK and SRC inhibitors in 
tumours expressing ILK. 
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Figure 1. Effect of bosutinib treatment on MDA-MB-231 and MCF-7 cell lines. A) Bosutinib 2D and 3D EC50 values 
in a panel of breast cancer cell lines. MDA-MB-157 and SKBR3 are unable to form spheroids. B) 3D spheroid cell 
viability. Spheroid area, Calcein-AM intensity and propidium iodide intensity were quantified using a custom 
CellProfiler pipeline. Staurosporine (1 µM) was used as a positive control to induce cell death. C) Western blot analysis 
of cell lines grown as 3D spheroids. Data are representative of two independent experimental replicates. D) Loss of ABL1 
does not alter bosutinib sensitivity. 2D bosutinib 8-point dilution for half-inhibitory concentrations (EC50). Additional 2D 
and 3D data are shown in Supplementary Figure 4. All data shown are the mean of at least three independent 
experimental replicates except MDA-MB-134-VI and MDA-MB-468 which were two independent experimental 
replicates. ***, p-value < 0.0002, ****, p-value < 0.0001, as determined by a two-way ANOVA with Bonferroni 
multiple comparisons correction. All error bars are S.E.M. 
Figure 2. The ILK-Parvin-PINCH complex is the top enhancer of bosutinib induced cell growth inhibition. A) 
Overview of the genome-wide CRISPR-Cas9 knockout screen in MDA-MB-231 cells. T0, initial timepoint immediately 
after puromycin selection; T7, 7 days post puromycin selection; T19, three rounds of drug treatment; T27, five rounds of 
drug treatment. B) DrugZ analysis of the genome-wide bosutinib CRISPR-Cas9 screen. The gene-level normalised Z-
score from the T27 time point is shown. Genes are ranked according to the enhancer genes. The Benjamini and Hochberg 
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(B&H) false-discovery rate (FDR) was used to calculate significance. Green data points are enhancer genes with FDR 
<0.05 and red are suppressor genes with FDR <0.05. C) Network map for the enhancer genes identified at T27. Network 
edges were weighted according to evidence of co-functionality using GeneMANIA in Cytoscape. D) ToppGene gene 
ontology analysis for the combined T19 and T27 enhancer genes. Blue, cellular component category; Yellow, pathway 
category. Black dots represent q-values. E) High ILK expression correlates with worse survival. Kaplan Meier plot for 
the METABRIC TNBC subtype. The optimal threshold for dichotomisation of the datasets into high and low ILK 
expression was identified using the survivALL R package and ‘plotALL’ function for multi-cut point analysis using the 
METABRIC dataset. F) Kaplan Meier plot for the TCGA-PanCancer basal subtype used as a validation dataset. Breast 
cancer-specific survival was used. 
Figure 3. Loss of the ILK-Parvin-PINCH complex potentiates the effects of bosutinib in MDA-MB-231 cells. A) 
CRISPR-Cas9 targeting ILK results in ILK loss in the MDA-MB-231 cell line as assessed by Western blot. B) Bosutinib 
8-point dose response curves using normalised cell counts form Hoechst-stained images. Significance test refers to EC50 
values calculated in Prism. C-G) Cells were treated with the EC20 for bosutinib (0.9 μM). C) ILK loss potentiates 
bosutinib inhibition in real-time assays. Cells were seeded in 96-well plates at 8,000 cells/well and transferred to the 
IncuCyte Zoom. Arrow shows drug addition at 24 h post seeding. D) End-point quantification using normalised cell 
confluence from the IncuCyte software. E) End-point quantification using normalised cell counts form Hoechst-stained 
images. F) Apoptosis assay using CellEvent Caspase 3/7 and fluorescence-activated cell sorting. All data shown are the 
mean of at least three independent experimental replicates. *, p-value < 0.05, ***, p-value < 0.001, ****, p-value < 
0.0001, as determined by a two-way ANOVA with Bonferroni multiple comparisons correction. All error bars are S.E.M. 
PX459v2, empty-gRNA CRISPR control cells; gRNA 1A, gRNA 1B and gRNA 2, ILK knockout clones. 
Figure 4. Loss of the ILK-Parvin-PINCH complex potentiates the effects of eCF506 in MDA-MB-231 cells. A) 
eCF506 8-point dilution for half-inhibitory concentrations (EC50). B) Apoptosis assay using CellEvent Caspase 3/7 and 
fluorescence-activated cell sorting. eCF506 treatment (40 nM; EC20). C) ILK loss potentiates eCF506 inhibition in real-
time. MDA-MB-231 cells were seeded in 96-well plates at 8,000 cells/well and transferred to the IncuCyte Zoom. Arrow 
shows drug addition. D) End-point quantification using normalised cell confluence from the IncuCyte software. E) End-
point quantification using normalised cell counts form Hoechst-stained images. C-E) An EC30 concentration for eCF506 
of 60 nM is shown. C-E, Data shown is the mean of two independent experimental replicates. * p-value < 0.05, **** p-
value < 0.0001, as determined by a two-way Anova with Bonferroni multiple comparisons correction. All error bars are 
S.E.M. PX459v2, empty-gRNA CRISPR control cells; gRNA 1A, gRNA 1B and gRNA 2, ILK knockout clones. 
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Figure 5. ILK loss in combination with bosutinib treatment results in differentially expressed genes. A) Principal 
component analysis using the Limma R package. B) Venn Diagram of differentially expressed genes. A cut-off of FDR 
(Benjamini & Hochberg) p-value adjustment <0.05 and a log2 fold change of ±1 was used for the differential expression 
analysis (DEA). Bosutinib EC20 (0.9 µM) used. Bosutinib DEA: PX459v2-DMSO vs PX459v2-bosutinib; ILK loss 
DEA: PX459v2-DMSO vs ILK gRNA 2-DMSO; ILK loss + bosutinib DEA: ILK gRNA 2-DMSO vs ILK gRNA 2-
bosutinib. Venn diagram created using the VennDiagram R package. C) Volcano plot of the 504 differentially expressed 
genes unique to ILK gRNA 2-bosutinib samples shown in B. The 504 unique genes were subject to a further cut-off of p-
value <0.05 (horizontal dotted blue line) and a log2 fold change of ±1 (vertical dotted blue lines) for ILK gRNA 2-
bosutinib vs PX459v2-bosutinib. D) Heatmap of the 134 unique and significantly changed genes shown in C, across all 
12 samples. Heatmap created using the ggplots R package. Euclidean distance and complete linkage clustering were 
used. E) ToppGene gene ontology analysis for the 134 unique DEGs. The top hits from the biological process category 
are shown. Black dots represent q-values. F) Integrin- collagen network map from the 134 unique DEGs created using 
GeneMANIA in Cytoscape. Associated genes were determined in GeneMANIA based on published databases and 
specific omics publications. 
Figure 6. ILK knockout in combination with bosutinib treatment causes cell adhesion defects. A) Western blot 
analysis of cell lines grown in 2D. Data are representative of three independent experimental replicates. B) Adhesion 
challenge: IncuCyte cell confluence was normalised to DMSO PX459v2. DMSO as solid fill, bosutinib as clear fill. C) 
2D 8-point dilution for half-inhibitory concentrations (EC50) for PND-1186. End-point quantification using normalised 
cell counts form Hoechst-stained images. D) Cell-by-cell mask and a ‘rounded cells’ classifier whereby area < 600 μm2 
and eccentricity <0.65, one hour post drug addition. E) IncuCyte S3 cell-by-cell quantification for MDA-MB-231 cells 
plated at 8,000 cells per well. Arrow shows drug addition. A bosutinib EC20 (0.9 μM) concentration was used in all 
experiments. 
Figure 7. ILK loss enhances bosutinib and eCF506 treatment in vivo. A) Tumour growth rates for PX459v2 and ILK 
gRNA 2 tumours growing in immunodeficient Rag2-Il2rg double knockout mice (5 mice per group, 2 tumours per 
mouse) following treatment with vehicle, bosutinib (75 mg/kg) or eCF506 (40 mg/kg) given once daily via oral gavage. 
B) Final tumour volumes at day 35. C) Bosutinib and eCF506 inhibit pSrc in vivo as shown via western blot. D) 
Quantification of westerns shown in C. E) Ki67 analysis using QuPath. ***, p-value < 0.0002, ****, p-value < 0.0001, as 
determined by a two-way ANOVA with Bonferroni multiple comparisons correction. All error bars are S.E.M. 
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